Novo Nordisk incretin leadership summit, Cape Town.
D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006801:Humans; D054795:Incretins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects; D013019:South Africa
D054795:Incretins; D052216:Glucagon-Like Peptide 1